• HIV-1 integrase inhibitor is useful for anti-HIV, with IC50 value of 0.33 µM, which can target HIV-1 integrase and depress the activity in the treatment of HIV infection, AIDS, and other similar diseases characterized by integration of a retroviral genome into a host chromosome. (apexbt.com)
  • Although antiretroviral drug toxicities in adults have been well documented, the effects of fetal and early childhood exposure to antiretroviral drugs on children of HIV-positive mothers are not well known. (omicsonline.org)
  • Results: The link between nucleoside analogs and mitochondrial dysfunction is controversial, and the association between in utero antiretroviral exposure and mitochondrial dysfunction in children is unclear. (omicsonline.org)
  • In utero exposure to antiretroviral therapy has effects on the heart, regardless of HIV status, including improved cardiac function but also reduced cardiac mass of unclear future clinical significance. (omicsonline.org)
  • In HIV-infected children, cumulative postnatal exposure to antiretroviral agents is associated with metabolic disturbances and an increased risk for cardiovascular disease. (omicsonline.org)
  • Further clinical trials and longitudinal monitoring are needed to understand the long-term effects of in utero exposure to antiretroviral agents. (omicsonline.org)
  • However, recent studies suggest that exposure to antiretroviral medications may have marked adverse effects, independent of HIV status [ 3 , 4 ]. (omicsonline.org)
  • Some health-care providers have proposed offering antiretroviral drugs to persons with unanticipated sexual or injecting-drug-use HIV exposure to prevent transmission. (cdc.gov)
  • To address concerns related to providing antiretroviral agents to persons after nonoccupational HIV exposure, CDC convened a meeting in July 1997 of scientists, public health experts, clinicians, members of professional associations, representatives from industry, ethicists, and members of affected communities. (cdc.gov)
  • Antiretroviral therapy should never replace adopting and maintaining behaviors that guard against HIV exposure (e.g., sexual abstinence, sex only with an uninfected partner, consistent and correct condom use, abstinence from injecting-drug use, and consistent use of sterile equipment by those unable to cease injecting-drug use). (cdc.gov)
  • Decisions to provide antiretroviral agents to persons after possible nonoccupational HIV exposure to prevent the establishment of HIV infection must balance the potential benefits and risks. (cdc.gov)
  • Methods: We searched the Pub Med database, reviewed publications, and selected abstracts on the use of antiretroviral agents to prevent HIV transmission and their effects on growth and cardiac endpoints in fetal and postnatal life. (omicsonline.org)
  • OBJECTIVES: To evaluate the pharmacokinetic features, safety, and tolerance of abacavir, given alone and in combination with other nucleoside antiretroviral agents, in symptomatic human immunodeficiency virus (HIV)-infected children. (elsevier.com)
  • Children then were randomized to receive a second nucleoside antiretroviral agent (zidovudine, stavudine, didanosine, or lamivudine), plus abacavir. (elsevier.com)
  • Combination antiretroviral therapy (ART) typically consists of two nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) plus a drug from another class such as an HIV protease inhibitor, a non-nucleoside reverse transcriptase inhibitor, an entry inhibitor or an integrase inhibitor. (aidsmap.com)
  • Several classes of anti-HIV drugs interfere with this stage of HIV's life cycle: nucleoside reverse transcriptase inhibitors and nucleotide reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs). (aidsmap.com)
  • Adding a small dose of a booster drug to an antiretroviral makes the liver break down the primary drug more slowly, which means that it stays in the body for longer times or at higher levels. (aidsmap.com)
  • Without the boosting agent, the prescribed dose of the primary drug would be ineffective. (aidsmap.com)
  • Other studies suggest a benefit if drug-resistance tests are used in selecting a new anti-HIV drug treatment. (ichgcp.net)
  • This study tests the effect of stopping anti-HIV drugs for a time before switching to anti-HIV drugs selected using drug-resistance test results. (ichgcp.net)
  • Studies suggest that treatment interruption prior to initiation of a multiple-drug rescue regimen may improve virologic response in individuals who have failed several prior antiretroviral regimens. (ichgcp.net)
  • Over the last four years, Caskey has led a series of first-in-human studies with two of the most promising broadly neutralizing anti-HIV-1 antibodies: 3BNC117 and 10-1074, which were isolated from HIV-infected individuals by the Laboratory of Molecular Immunology. (google.com)
  • Studies show that stopping all anti-HIV drugs for a time before switching to new anti-HIV drugs may improve the response in some individuals who are failing treatment. (ichgcp.net)